Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus QBREXZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus QBREXZA.
LUSEDRA vs QBREXZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
5 mg orally once daily.
1 capsule (40 mg) orally twice daily with or without food.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination.
Category C
Category C
Anticholinergic
Anticholinergic